GLP-1 Ripple Effects Reach the Grocery Aisle: Cornell Finds 5–8% Grocery-Spend Decline After Adoption

GLP-1 Ripple Effects Reach the Grocery Aisle: Cornell Finds 5–8% Grocery-Spend Decline After Adoption

The second-order economic effects of GLP-1 adoption are now measurable in consumer data. A Cornell University study of household purchase data found that "grocery spending fell about 5% within six months of a household adopting a GLP-1, and that increased to more than 8% for higher-income households¹" — with the dip shrinking over time and fading once people stop the drug. That puts a quantified demand headwind on packaged-food names: "Confectionery, chocolate, and savory snacks are at risk," threatening sales of Doritos, Lay's, Hershey's, Cheetos, Toblerone, and Reese's — and "puts a target on companies like PepsiCo (PEP), The Hershey Company (HSY), and Mondelez (MDLZ)." PepsiCo is flagged as the weakest of the three, "with North American snack volumes and pricing both under pressure, and an activist investor now pushing for change"; Hershey's problems are mostly cocoa costs, and Mondelez has held up best on emerging-market exposure — but "GLP-1 will add real pressure on top of these problems."

The scale of the underlying adoption wave explains why food companies are treating this as structural rather than cyclical: Morgan Stanley projects global diabetes-plus-obesity drug sales of $190B by 2035, more than double the ~$79B recorded in 2025, and JPMorgan estimates ~10 million Americans were on GLP-1s in 2025, reaching 25–30 million by 2030 with pills, lower prices, and Medicare access as drivers. On the medtech side, the efficacy trajectory is the threat: Lilly's retatrutide delivered 28.3% average weight loss at 80 weeks in TRIUMPH-1, against the 25–35% typical of bariatric surgery — meaning "GLP-1 drugs are close to reproducing the same result as a major medical procedure," the pharmacological substitute for bariatric volume. The payer side of the ripple is tracked separately in Employers Roll Back GLP-1 Coverage for Weight Loss as Exploding Demand and New Oral Options Fuel Cost Concerns and Medicare GLP-1 Bridge Reaches 700K Seniors at $50 Copay; Lilly Cuts Foundayo Starter Doses to $149.